<DOC>
	<DOCNO>NCT01009281</DOCNO>
	<brief_summary>This study ass safety tolerability AIN457 patient moderate severe Crohn 's disease already participate complete core trial CAIN457A2202 .</brief_summary>
	<brief_title>An Open Label Safety Tolerability Study AIN457 Patients With Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients participate complete core CAIN457A2202 study include Visit 11 ( end study ) , may enter extension study upon sign informed consent . Patients continue treatment AIN457 consider appropriate treating physician . Patients noncompliant demonstrate mahor protocol violation core CAIN457A2202 study Patients discontinue core CAIN457A2202 study end study . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Crohns</keyword>
	<keyword>Bowel disease</keyword>
	<keyword>digestive disorder</keyword>
	<keyword>auto immune</keyword>
	<keyword>diarrhea</keyword>
	<keyword>Inflammatory Bowel Disease ( IBD )</keyword>
	<keyword>gastrointestinal disease</keyword>
	<keyword>digestive system disease</keyword>
	<keyword>Antibody</keyword>
	<keyword>IL 17</keyword>
	<keyword>anti IL-17</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>Crohn 's Disease ( Chron 's , CD )</keyword>
</DOC>